HC Wainwright Reiterates "Buy" Rating for Travere Therapeutics (NASDAQ:TVTX)

Key Points

• HC Wainwright has reiterated a "buy" rating for Travere Therapeutics (NASDAQ:TVTX), setting a price target of $47.00, indicating a potential upside of 142.39% from the stock's previous close.
• Travere Therapeutics reported earnings of ($0.14) EPS for the last quarter, surpassing analysts' estimates, with revenue growing by 111.5% year-over-year.
• Thirteen analysts have rated Travere with a buy rating and the company currently has a consensus price target of $33.43.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report)'s stock had its "buy" rating restated by analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $47.00 price target on the stock. HC Wainwright's price target suggests a potential upside of 142.39% from the stock's previous close. HC Wainwright also issued estimates for Travere Therapeutics' FY2026 earnings at ($0.25) EPS, FY2027 earnings at $0.95 EPS, FY2028 earnings at $2.54 EPS and FY2029 earnings at $3.28 EPS.

TVTX has been the subject of a number of other research reports. Wedbush boosted their price objective on Travere Therapeutics from $30.00 to $32.00 and gave the stock an "outperform" rating in a report on Thursday, August 7th. Citigroup reissued a "buy" rating on shares of Travere Therapeutics in a report on Sunday, August 10th. Wall Street Zen upgraded Travere Therapeutics from a "hold" rating to a "buy" rating in a research note on Monday. Finally, Scotiabank reaffirmed an "outperform" rating on shares of Travere Therapeutics in a report on Thursday, August 7th. Thirteen equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $33.43.

Travere Therapeutics Stock Performance

TVTX stock traded up $1.24 during midday trading on Wednesday, reaching $19.39. 211,506 shares of the company were exchanged, compared to its average volume of 1,644,026. Travere Therapeutics has a one year low of $9.34 and a one year high of $25.29. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of -9.54 and a beta of 0.79. The business has a 50-day moving average price of $16.48 and a two-hundred day moving average price of $17.35. The company has a debt-to-equity ratio of 9.50, a current ratio of 2.00 and a quick ratio of 1.98.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.14. The company had revenue of $94.84 million during the quarter, compared to analysts' expectations of $100.18 million. Travere Therapeutics had a negative net margin of 50.64% and a negative return on equity of 717.68%. Travere Therapeutics's quarterly revenue was up 111.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.65) EPS. Equities research analysts forecast that Travere Therapeutics will post -1.4 EPS for the current year.

Institutional Trading of Travere Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new position in Travere Therapeutics in the fourth quarter valued at approximately $31,000. Raymond James Financial Inc. bought a new stake in Travere Therapeutics during the second quarter worth $33,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Travere Therapeutics in the 1st quarter valued at $62,000. Gen Wealth Partners Inc bought a new position in shares of Travere Therapeutics in the 4th quarter valued at $73,000. Finally, Headlands Technologies LLC bought a new position in shares of Travere Therapeutics in the 2nd quarter valued at $73,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.